TY - JOUR
T1 - New immunoassays for total, IgA and IgM antibodies against hepatitis E virus
T2 - Prevalence in Italian blood donors and patients with chronic liver or kidney diseases
AU - Ricco, Gabriele
AU - Bonino, Ferruccio
AU - Lanza, Maria
AU - Scatena, Fabrizio
AU - Alfieri, Carlo M.
AU - Messa, Piergiorgio
AU - Marchisio, Edoardo
AU - Mascolo, Giovanni
AU - Romanò, Luisa
AU - Galli, Cristina
AU - Li, Tian Cheng
AU - Wakita, Takaji
AU - Miyamura, Tatsuo
AU - Brunetto, Maurizia R.
PY - 2016
Y1 - 2016
N2 - Background: Hepatitis E virus (HEV) is a zoonotic agent that causes acute hepatitis in humans with sporadic infections and outbreaks in developing countries worldwide. The global spread of HEV remains underestimated because of subclinical infections and lack of sensitive diagnostic assays. Aims: To study the prevalence of HEV antibodies (anti-HEV) in sera of blood-donors and patients with chronic-liver-disease and chronic-renal-disease, using newly developed anti-HEV assays. Methods: 396 sera from 199 blood-donors, 109 chronic-liver-disease patients and 88 chronic-renal-disease patients and three standard reference serum panels were tested in parallel with a sensitive reference anti-HEV assay and newly developed assays for IgA, IgM and total anti-HEV based on HEV-like-particles produced by recombinant baculo-viruses. Results: Overall, total anti-HEV was detected in 12.9% (7.0% blood-donors, 9.2% and 30.7% chronic-liver-disease patients and chronic-renal-disease patients, respectively). We observed a higher anti-HEV prevalence in older subjects and in chronic-renal-disease patients in relation with degree on immune-depression (p
AB - Background: Hepatitis E virus (HEV) is a zoonotic agent that causes acute hepatitis in humans with sporadic infections and outbreaks in developing countries worldwide. The global spread of HEV remains underestimated because of subclinical infections and lack of sensitive diagnostic assays. Aims: To study the prevalence of HEV antibodies (anti-HEV) in sera of blood-donors and patients with chronic-liver-disease and chronic-renal-disease, using newly developed anti-HEV assays. Methods: 396 sera from 199 blood-donors, 109 chronic-liver-disease patients and 88 chronic-renal-disease patients and three standard reference serum panels were tested in parallel with a sensitive reference anti-HEV assay and newly developed assays for IgA, IgM and total anti-HEV based on HEV-like-particles produced by recombinant baculo-viruses. Results: Overall, total anti-HEV was detected in 12.9% (7.0% blood-donors, 9.2% and 30.7% chronic-liver-disease patients and chronic-renal-disease patients, respectively). We observed a higher anti-HEV prevalence in older subjects and in chronic-renal-disease patients in relation with degree on immune-depression (p
KW - Assay
KW - Epidemiology
KW - HEV
KW - Virus-Like Particles (V-LPs)
UR - http://www.scopus.com/inward/record.url?scp=84959191748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959191748&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2016.01.007
DO - 10.1016/j.dld.2016.01.007
M3 - Article
AN - SCOPUS:84959191748
VL - 48
SP - 536
EP - 541
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 5
ER -